Survodutide

Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake1.

In Vitro

The EC50 is 0.36 nM for Survodutide (BI 456906) in the endogenous mouse GLP-1R in the insulinoma cell line MIN6, and the EC50 is 60 pM for GLP-1. In 0.5% human and mouse plasma, Survodutide shows a similar potency to that of endogenous GLP-1. For the GCGR, in 0.5% human and mouse plasma, Survodutide is 6-fold less potent (0.29 and 0.17 nM, respectively) in relation to endogenous glucagon (47 and 30 pM, respectively)1.

Proteolytic stability of Survodutide is helped by C-terminal amidation and the introduction of a non-coded amino acid 1-aminocyclobutane-1-carboxylic acid (Ac4c) in position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4. The desired extended terminal half-life of Survodutide is achieved by the introduction of a glycine–serine linker in position 24, carrying a C18 di-acid1.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Survodutide Related Antibodies

GLP-1R Antibody

Glucagon Antibody (YA921)

delta Sarcoglycan Antibody (YA3326)

gamma Synuclein/SNCG Antibody (YA1357)

In Vivo

Survodutide (BI 456906; 3, 10, 20, 30 nmol/kg; SC; daily; 30 days) achieves a greater bodyweight-lowering efficacy in diet-induced obese mice compared with maximally effective doses of Semaglutide (HY-114118; 20, 100 nmol/kg). Survodutide dose-dependently reduces plasma glucagon1.

Survodutide (1, 3, 10, 30, 100 nmol/kg; SC; single dose) dose-dependently reducesacute food intake in WT but not in GLP-1R KO mice (Three-week-old, male, lean NMRI outbred mice)1.

Survodutide (1, 3, 10, 30, 100 nmol/kg; SC; single dose) engages the glucagon receptor in vivo upon single dosing, increases liver nicotinamide N-methyltransferase mRNA, and reduces plasma serine and glutamine1.

Survodutide (SC injection) causes mean residence times of 44 and 140 h and Tmax values of 7 and 51 h obtained in mice and dogs, respectively1.

Pharmacokinetic Parameters of Survodutide (BI 456906) in mice and dogs